[1]薛 姣,肖海峰,姜南艳,等.肝硬化患者血浆胆碱酯酶活性对麻醉剂米库氯铵代谢的影响[J].现代检验医学杂志,2019,34(05):124-126.[doi:10.3969/j.issn.1671-7414.2019.05.030]
　XUE Jiao,XIAO Hai-feng,JIANG Nan-yan,et al.Effects of Plasma Cholinesterase Activity on the Metabolism of Mivacurium(Anesthetic)in Patients with Hepatocirrhosis[J].Journal of Modern Laboratory Medicine,2019,34(05):124-126.[doi:10.3969/j.issn.1671-7414.2019.05.030]
点击复制

肝硬化患者血浆胆碱酯酶活性对麻醉剂米库氯铵代谢的影响()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年05期
页码:
124-126
栏目:
研究简报·实验技术
出版日期:
2019-10-29

文章信息/Info

Title:
Effects of Plasma Cholinesterase Activity on the Metabolism of Mivacurium(Anesthetic)in Patients with Hepatocirrhosis
文章编号:
1671-7414(2019)05-124-03
作者:
薛 姣1; 肖海峰2; 姜南艳1; 董 珂1
(1.空军军医大学第二附属医院检验科,西安 710038; 2.解放军987医院麻醉科,陕西宝鸡 721000)
Author(s):
XUE Jiao1; XIAO Hai-feng2; JIANG Nan-yan1; DONG Ke1
(1.Department of Clinical Laboratory,the Second Affiliated Hospital of the Air Force Military Medical University,Xi'an 710038,China; 2.Department of Anesthesiology,the No.987 Hospital of the PLA,ShaanxiBaoji 721000,China)
关键词:
肝硬化;  血浆胆碱酯酶;  米库氯铵
分类号:
R575.2; R446.112
DOI:
10.3969/j.issn.1671-7414.2019.05.030
文献标志码:
A
摘要:
目的 探讨肝硬化患者血浆胆碱酯酶(plasma cholinesterase,PchE)活性对麻醉剂米库氯铵代谢的影响,为临床麻醉提供指导。方法 选取2016年10月～2018年10月接受全麻手术的患者70例,分为肝硬化组(n=35)和非肝硬化组(n=35),麻醉开始前采集静脉血检测PchE活性,使用同样的麻醉药物及麻醉方法,肌松监测采用四个成串刺激(train of four stimulation,TOF)。首次给予米库氯铵后记录作用时间(首剂作用时间),术中维持阶段采用持续泵注,手术结束前停止泵注的时间肝硬化组早于非肝硬化组10 min,然后分别记录四个成串刺激比值(train of four stimulation ratio,TOFr)恢复到25%,50%和75%的时间。术中记录的一般观察指标为手术时长、出血量和输液量。最后分析两组间PchE的活性和恢复时间之间的关系。结果 肝硬化组的PchE活性(4 174±799U/L)明显低于非肝硬化组(6 274±1 151U/L),差异有统计学意义(t=8.865,P=0.000)。肝硬化组的首剂作用时间(20.3±3.7 min)长于非肝硬化组(16.3±3.3min),差异有统计学意义(t=4.767,P=0.000)。肝硬化组的TOFr恢复到25%,50%和75%的时间(26.2±8.0,31.8±8.3,33.8±10.6 min)明显长于非肝硬化组(16.0±4.0,20.4±3.9,24.1±4.6 min),差异均有统计学意义(t=6.683,P=0.000; t=7.355,P=0.000; t=4.960,P=0.000)。两组患者的手术时长、出血量、输液量比较,差异均无统计学意义(t=1.227,P=0.224; t=0.643,P=0.000; t=1.624,P=0.109)。结论 肝硬化患者的PchE活性明显下降,对米库氯铵的代谢时间延长,掌握其代谢特点对临床麻醉有重要意义。
Abstract:
Objective To investigate the effects of PchE activity on the metabolism of mivacurium(Anesthetic)in patients with hepatocirrhosis,and provide a guidance for clinical anesthesia.Methods 70 patients who received operation were selected from October 2016 to October 2018.All patients were divided into ahepatocirrhosis group(n=35)anda non hepatocirrhosis group(n=35).To detect PchE activity by collecting venous blood before the start of anesthesia.Every patient was used the same anesthetics and anesthesia methods.Muscular relaxation monitor was applied with a train of four stimulation(TOF).To record the time of action after the first administration of mivacurium(first dose time).Continuou pumping was used during the maintenance phase of operation.The time of stopping pumping before the end of operation in hepatocirrhosis group was 10 minutes earlier than that in non hepatocirrhosis group,and record the times of TOFr(recovery to 25%,50% and 75%).The general observational indexes recorded during the operation were the length of operation,the amount of bleeding and the amount of infusion.Lastly,the relationship between PchE activity and recovery time between the two groups was analyzed.Results The PchE activity was less in the hepatocirrhosis group(4 174±799 U/L)compared with non hepatocirrhosis group(6 274±1 151 U/L)significantly(t=8.865,P=0.000).The duration of the first dose were 20.3±3.7 min,16.3±3.3 min respectively(t=4.767,P=0.000).The recovery time of TOFr(recovery to 25%,50% and 75%)were 26.2±8.0,31.8±8.3,33.8±10.6 min in hepatocirrhosis group,and 16.0±4.0,20.4±3.9,24.1±4.6 min in non hepatocirrhosis group.There were significant differences between the two groups(t=6.683,P=0.000; t=7.355,P=0.000; t=4.960,P=0.000).There were no significant differences in the length of operation,the amount of bleeding and the amount of infusion between the two groups(t=1.227,P=0.224; t=0.643,P=0.000; t=1.624,P=0.109).Conclusion The activity of PchE in patients with hepatocirrhosis was significantly decreased, and the metabolic time of mivacurium was prolonged.It isimportant for clinical anesthesia to master the metabolic characteristics of mivacurium.

参考文献/References:

[1] KIAMANESH D,RUMLEY J,MOITRA V K.Monitoring and managing hepatic disease in anaesthesia[J].Br J Anaesth,2013,111(1):50-61. [2] 谭建荣,罗显克,王大东,等.肝硬化患者血清胆碱酯酶和腺苷脱氨酶联合检测的临床意义[J].现代生物医学进展,2014,14(8):1494-1496. TAN Jianrong,LUO Xianke,WANG Dadong,et al.The clinical significance of cirrhosis combined detection serum cholinesterase and adenosine deaminase[J].Progress in Modern Biomedicine,2014,14(8):1494-1496. [3] 马正甲.血清胆碱酯酶测定在重症肝炎病情判断中的应用价值[J].检验医学与临床,2013,10(9):1141-1142. MA Zhengjia.Application value of serum cholinesterase determinationin judging the severity of severe hepatitis[J].Laboratory Medicine and Clinic,2013,10(9):1141-1142. [4] ZABIHI E,SHABANZADEH M,ARABSHEIBANI S,et al.Pseudo-cholinesterase polymorphism in Mazandaran province(North of Iran)[J].Caspian J Intern Med,2012,3(3):473-477. [5] DELACOUR H,LUSHCHEKINA S,MABBOUX I,et al.Characterization of a novelbutyrylcholinesterase point mutation(p.Ala34Val),“silent”with mivacurium[J].Biochem Pharmacol,2014,92(3):476-483. [6] CASSEL J,STAEHR-RYE A K,NIELSEN C V,et al.Use of neuromuscular monitoring to detect prolonged effect of succinylcholine or mivacurium:three case reports[J].Acta Anaesthesiol Scand,2014,58(8):1040-1043. [7] 赵启东,刘斌.非去极化肌松药在特殊病人的临床应用进展[J].现代临床医学,2009,35(5):394-397. ZHAO Qidong,LIU Bin.Progress in the clinical application of non-depolarizing muscle relaxants in special patients[J].Journal of Modern Clinical Medicine,2009,35(5):394-397. [8] DEVLIN J C,HEAD-RAPSON A G,PARKER C J,et al.Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis[J].Br J Anaesth,1993,71(2):227-231.

相似文献/References:

[1]杨渝伟,黄玉霞,陈小红,等.胱抑素C及其eGFR方程在诊断肝硬化患者肾损害中的应用[J].现代检验医学杂志,2016,31(04):24.[doi:10.3969/j.issn.16717-414.2016.04.006]
　YANG Yu-wei,HUANG Yu-xia,CHEN Xiao-hong,et al.Clinical Application of Cystatin C and It's eGFR Equation for Diagnosing Kidney Injure in Patients with Liver Cirrhosis[J].Journal of Modern Laboratory Medicine,2016,31(05):24.[doi:10.3969/j.issn.16717-414.2016.04.006]
[2]刘昌贺,李　衡,徐圣杰,等.肝硬化伴肝性脑病与血清IL-6表达水平相关性的meta分析[J].现代检验医学杂志,2022,37(03):56.[doi:10.3969/j.issn.1671-7414.2022.03.012]
　LIU Chang-he,LI Heng,XU Sheng-jie,et al.Meta Analysis of the Correlation between Serum Interleukin-6 and Hepatic Encephalopathy in Liver Cirrhosis[J].Journal of Modern Laboratory Medicine,2022,37(05):56.[doi:10.3969/j.issn.1671-7414.2022.03.012]
[3]赵佳慧,余 雯.乙型肝炎肝硬化患者血清miR-25-3p 和IBSP 表达及临床意义[J].现代检验医学杂志,2022,37(04):96.[doi:10.3969/j.issn.1671-7414.2022.04.019]
　ZHAO Jia-hui,YU Wen.Expression and Clinical Significance of Serum miR-25-3p and IBSP in Patients with Hepatitis B Cirrhosis[J].Journal of Modern Laboratory Medicine,2022,37(05):96.[doi:10.3969/j.issn.1671-7414.2022.04.019]
[4]冯 瑾,魏绪仓.肝硬化患者骨髓造血系统异常的机制研究进展及其骨髓细胞学检查的临床意义[J].现代检验医学杂志,2023,38(02):200.[doi:10.3969/j.issn.1671-7414.2023.02.038 ]
　FENG Jin,WEI Xu-cang.Research Progress on the Mechanism of Bone Marrow Hematopoietic System Abnormalities in Patients with Liver Cirrhosis and Its Clinical Significance of Bone Marrow Cytology[J].Journal of Modern Laboratory Medicine,2023,38(05):200.[doi:10.3969/j.issn.1671-7414.2023.02.038 ]

备注/Memo

备注/Memo:
作者简介:薛 姣(1986-),女,本科,主管技师,主要从事急诊检验,E-mail:275107598@qq.com。 通讯作者:董 珂,男,E-mail:drdongke@163.com。
更新日期/Last Update: 2019-10-20